Johnson & Johnson (JNJ) reported positive data from a late stage study of Tremfya for the treatment of active psoriatic arthritis.
The study showed that Tremfya, when used as a first-line treatment, significantly slows down radiographic progression by Week 24, with these benefits continuing through Week 48.
Additionally, over 50% of patients treated with Tremfya in both dosage groups experienced a 50% improvement in their psoriatic arthritis symptoms by Week 48, according to the study results.
The findings align with Tremfya’s established safety profile, showing no new safety concerns, the company said.